



Oregon Prescription Drug Affordability Board

350 Winter Street NE, Salem, OR 97309-0405 | 971-374-3724 | pdab@dcbs.oregon.gov | dfr.oregon.gov/pdab

Agenda

This is a regular meeting. **Date: September 17, 2025** | **Time: 8 a.m.**

This is a draft agenda and subject to change

Board Members:

Chair Shelley Bailey
Vice Chair Dr. Amy Burns
Dr. Daniel Hartung
Dr. Christopher Laman
John Murray
Dan Kennedy
Lauri Hoagland

Meeting name

Prescription Drug Affordability Board

Meeting location

Virtual

Zoom link

[Register for meeting](#)

Staff: Cortnee Whitlock, senior policy analyst; Stephen Kooyman, project manager, Heather Doyle, data analyst; Pei-Chen Choo, research analyst; Melissa Stiles, administrative specialist; Pramela Reddi, counsel

| Purpose | Subject | Presenter |
|-------------------------------|--|---|
| <i>Informational and vote</i> | Call to order and roll call | Chair Shelley Bailey |
| <i>Informational</i> | Board declarations of conflict of interest and meetings with entities or individuals related to board activities | Chair Shelley Bailey |
| <i>Discussion and vote</i> | Board approval of 8/20/2025 minutes | Chair Shelley Bailey |
| <i>Informational</i> | PDAB program update | Cortnee Whitlock, senior policy analyst |
| <i>Informational</i> | General public comment: limited to 3 minutes | Chair Shelley Bailey |
| <i>Discussion</i> | Volunteered trade secret information | Cortnee Whitlock |
| <i>Review and discussion</i> | Policy recommendations for including in the 2025 annual legislative report | Cortnee Whitlock |
| <i>Review and discussion</i> | Methodology for drug reviews and scoring rubric and worksheet | Cortnee Whitlock |
| <i>Review and discussion</i> | Drug review: Jardiance – Antidiabetics ¹ | Cortnee Whitlock |

¹ The board is conducting drug reviews per ORS 646A.694 and OAR 925-200-0020. There will be a public comment period for the prescription drug selected for cost review. Each speaker will have 3 minutes. Board members may have follow-up questions for the speakers. The board chair has the discretion to extend a speaker's time. The board will hear from patients, caregivers, and individuals with scientific or medical background, per ORS 646A.694(3).

| Purpose | Subject | Presenter |
|------------------------------|---|----------------------|
| <i>Review and discussion</i> | Drug review: Mounjaro – Antidiabetics ¹ | Cortnee Whitlock |
| <i>Review and discussion</i> | Drug review: Ozempic – Antidiabetics ¹ | Cortnee Whitlock |
| <i>Review and discussion</i> | Drug review: Rybelsus – Antidiabetics ¹ | Cortnee Whitlock |
| <i>Review and discussion</i> | Drug review: Trulicity – Antidiabetics ¹ | Cortnee Whitlock |
| <i>Break</i> | The board will take a break around 10:30 | Chair Shelley Bailey |
| <i>Informational</i> | Announcements | Chair Shelley Bailey |
| <i>Vote</i> | Adjournment | Chair Shelley Bailey |

Accessibility

Anyone needing assistance due to a disability or language barrier can contact Melissa Stiles at least 48 hours ahead of the meeting at pdab@dcbs.oregon.gov or 971-374-3724. American sign language will be available during the September 17 board meeting.

How to provide testimony to the board

The Prescription Drug Affordability Board invites people to provide testimony. **Oral:** To speak to the board during the public comment portion of the agenda, please submit the [PDAB public comment form](#) no later than 24 hours before the PDAB meeting. **Written:** to provide written comments to the board, please submit the [PDAB public comment form](#) with attachments no later than 48 hours before the PDAB meeting. The board reviews all written comments. All written comments are posted on the website.

Open and closed sessions

All board meetings except executive sessions are open to the public. Pursuant to ORS 192.660, executive sessions are closed to everyone but board members, designated staff, and members of the news media. No action will be taken in executive session. Members of the media are directed not to report on or otherwise disclose anything said during executive session.

¹ The board is conducting drug reviews per ORS 646A.694 and OAR 925-200-0020. There will be a public comment period for the prescription drug selected for cost review. Each speaker will have 3 minutes. Board members may have follow-up questions for the speakers. The board chair has the discretion to extend a speaker's time. The board will hear from patients, caregivers, and individuals with scientific or medical background, per ORS 646A.694(3).